Companies / LTP

LTR PHARMA LIMITED

ASX:LTPPharmaceuticals, Biotechnology & Life Sciences
181.8M shares on issueASX (delayed) · as of 28 July 2026$0.51price · delayed$89.1Mmarket cap · indicative
D
Dilution grade

Share count grew 114% in 24 months; runway 2–4 quarters; options/rights overhang 22% of shares

Cash runway3.7 quarters of funding
Share-count growth (24m)114.4%
Raise cadence (24m)0 cash raises
Options & rights overhang22.1% of shares
In-the-money supply6.0% of shares
Pending proposed issuesnone

LTR PHARMA LIMITED's ordinary share count grew 114.4% between July 2024 and February 2026, to 182M shares. The company did not raise capital in the 24‑month window covered. Options and rights on issue could convert into 40M new shares, equal to 22.1% of the current share count, of which 6% are in the money at the current share price; the nearest expiry is December 2026. At the June 2026 quarter LTR PHARMA LIMITED reported A$18.1M in available cash, equivalent to 3.7 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
22.1%
Max option dilution
6.0%
ITM option dilution
0
Raises · last 12 months
3.7 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 181.8M per ASX (delayed) (28 July 2026).
159.7M167.8M175.9MDec 24Sept 25July 26

Cash runway

3.7 qtrs
Two to four quarters of funding at the recent spend rate.
$18.1M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
10 July 20263G · unquotedORDINARY FULLY PAID181.8MAppendix 3G
10 Feb 20262A · quoted issueLTP : ORDINARY FULLY PAID181.8MAppendix 2A
21 Jan 20262A · quoted issueLTP : ORDINARY FULLY PAID181.7MAppendix 2A
16 Jan 20263G · unquotedLTP : ORDINARY FULLY PAID181.6MAppendix 3G
22 Dec 20253G · unquotedLTP : ORDINARY FULLY PAID181.6MAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

22.1%
Total overhang · of current shares
6.0%
In the money · at current price
40.2M
Potential new shares
Dec 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
19 Nov 2025Lee RodneOther51.4M3.0M—3Y notice
19 Nov 2025Julian ChickOther808k1.5M—3Y notice
19 Nov 2025Maja McGuireOther235k1.0M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
19 July 2026$PLTR Executes U.S. Commercial Agreement with Strive
16 July 2026$PLTR Executes Definitive U.S. Commercial Agreement with Shed
10 July 2026Notification regarding unquoted securities - LTP
23 June 2026OROFLOW Clinical Study Receives Ethics Approval
15 June 2026$PResponse to ASX Aware Letter
10 June 2026$PLTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
8 June 2026$PLTR Secures First U.S. Commercial Agreement for ROXUS
30 Apr 2026$PInvestor Presentation
30 Apr 2026$PSPONTAN Phase II data show rapid onset, support FDA pathway
28 Apr 2026$PTrading Halt
27 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
10 Mar 2026Investor Presentation
4 Mar 2026$PSPONTAN Phase II Clinical Study Completes Recruitment
25 Feb 2026$PAppendix 4D and Half Yearly Report
10 Feb 2026Application for quotation of securities - LTP
1 Feb 2026$PSPONTAN Shows Positive Outcomes in Younger Men with ED
27 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
21 Jan 2026$PFirst Patients Dosed in SPONTAN Phase II Clinical Study
21 Jan 2026Application for quotation of securities - LTP

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.